Effect of Heart Rate on Left Ventricular Performance
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01112176|
Recruitment Status : Unknown
Verified April 2010 by Hillel Yaffe Medical Center.
Recruitment status was: Recruiting
First Posted : April 28, 2010
Last Update Posted : April 28, 2010
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Function Myocardial Strain||Procedure: Increase in paced heart rate||Not Applicable|
Participants will be patients with pacemakers and normal A-V node conduction with a possibility for right atrial pacing mode.
Detailed Echo studies will be performed at baseline. Echo studies will be repeated at each pacing stage, stages defined as 10 bpm increments in paced heart rate. Each stage will last 2-3 min or as long as it takes to record the echo study. Heart rate will be increased to 85% of predicted heart rate for age or at to appearance of signs of ischemia.
Hemodynamic parameters will be recorded and segmental longitudinal strain will be calculated (as well as other Echo data), for each stage.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Effect of Heart Rate on Left Ventricular Performance|
|Study Start Date :||April 2010|
|Estimated Primary Completion Date :||April 2012|
|Estimated Study Completion Date :||April 2012|
- Procedure: Increase in paced heart rate
The pacing rate will be increased by 10 bps at every stage
- Segmental Strain [ Time Frame: approx. 20 minutes ]Segmental Strain by speckle tracking method will be calculated for every stage of each study.
- LV function [ Time Frame: Approx. 20 minutes ]Parameters of systolic and diastolic function will be calculated at each stage.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01112176
|Contact: David S. Blondheim, MDemail@example.com|
|Contact: David S. Blondheim, MD|
|Hille Yaffe Medical Ceter||Recruiting|
|Hadera, Israel, 38100|
|Contact: David Blondheim, MD 97246304488 firstname.lastname@example.org|
|Principal Investigator: David S. Blondheim, MD|
|Principal Investigator:||David S. Blondheim, MD||Hillel Yaffe Medical Center|